VCYT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VC

Mkt Cap

$3.47B

Volume

1.08M

Next Earnings

November 3rd

Loading chart

VC

VCYTVeracyte, Inc.

VCYT

Pay with—

Available Balance0.00

VC

Mkt Cap

$3.57B

Volume

1.08M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech FirmsVeeva Systems announced that over 175 emerging biotech companies are adopting Veeva Basics to streamline drug development operations. The pre-configured platform helps smaller biotechs establish technology infrastructure for clinical, regulatory, and quality processes. Growing adoption could support long-term revenue growth as these companies expand, though financial impact depends on customer retention and conversion to meaningful revenue.Zacks Investment Research · Oct 13, 2026

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YAngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.Zacks Investment Research · Oct 9, 2026

Reasons to Hold Veeva Systems Stock in Your Portfolio for NowVeeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates.Zacks Investment Research · Oct 9, 2026

Is it the Right Time to Add Phibro Stock to Your Portfolio?Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.Zacks Investment Research · Oct 8, 2026

Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsSmith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR.Zacks Investment Research · Oct 8, 2026

Bruker Gains 66.3% in a Year: What's Driving the Rally?Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.Zacks Investment Research · Oct 8, 2026

Reasons to Hold HealthEquity Stock in Your Portfolio for NowHealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability.Zacks Investment Research · Oct 7, 2026

Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesVeeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market.Zacks Investment Research · Oct 7, 2026

Reasons to Add Globus Medical Stock to Your Portfolio NowGlobus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.Zacks Investment Research · Oct 7, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally?Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 7, 2026

to start trading

VC

VCYTVeracyte, Inc.

VCYT

Pay with—

Available Balance0.00

Your PositionYou don't own any VCYT yet.

Related Tickers

Earnings